Abstract
Lymphoid malignancies may affect the eye either as primary intraocular lymphomas (PIOL), or by secondary involvement of a nodal lymphoma. PIOL is a subtype of primary central nervous system (CNS) lymphoma and in up to 98% of the cases are non- Hodgkins B cell lymphomas. PIOL may occur in isolation, without involvement of the CNS. They may affect both the vitreous and the retina, while secondary invasion predominantly affects the uvea. Both forms frequently masquerade as intraocular inflammation or uveitis. Systemic chemotherapy, alone or in combination with radiotherapy has been used in the past for the treatment of PIOL. Methotrexate and rituximab are immunomodulatory agents used in the treatment of cancer and autoimmune diseases. Recent reports have shown the intraocular safety and efficacy of both of these agents for the treatment of PIOL.
Keywords: Ocular malignancy, ocular lymphoma, central nervous system lymphoma, reticulum cell sarcoma, non-Hodgkin's B cell lymphomas, masquerade syndrome, methotrexate and rituximab
Anti-Cancer Agents in Medicinal Chemistry
Title: Local Treatment for Lymphoid Malignancies of the Eye
Volume: 9 Issue: 10
Author(s): Gian Paolo Giuliari, David M. Hinkle and C. Stephen Foster
Affiliation:
Keywords: Ocular malignancy, ocular lymphoma, central nervous system lymphoma, reticulum cell sarcoma, non-Hodgkin's B cell lymphomas, masquerade syndrome, methotrexate and rituximab
Abstract: Lymphoid malignancies may affect the eye either as primary intraocular lymphomas (PIOL), or by secondary involvement of a nodal lymphoma. PIOL is a subtype of primary central nervous system (CNS) lymphoma and in up to 98% of the cases are non- Hodgkins B cell lymphomas. PIOL may occur in isolation, without involvement of the CNS. They may affect both the vitreous and the retina, while secondary invasion predominantly affects the uvea. Both forms frequently masquerade as intraocular inflammation or uveitis. Systemic chemotherapy, alone or in combination with radiotherapy has been used in the past for the treatment of PIOL. Methotrexate and rituximab are immunomodulatory agents used in the treatment of cancer and autoimmune diseases. Recent reports have shown the intraocular safety and efficacy of both of these agents for the treatment of PIOL.
Export Options
About this article
Cite this article as:
Giuliari Paolo Gian, Hinkle M. David and Foster Stephen C., Local Treatment for Lymphoid Malignancies of the Eye, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (10) . https://dx.doi.org/10.2174/187152009789735071
DOI https://dx.doi.org/10.2174/187152009789735071 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunomodulatory Drugs (IMiDs™): A New Treatment Option for Myelodysplastic Syndromes
Current Pharmaceutical Biotechnology Pituitary Stem Cells Drop Their Mask
Current Stem Cell Research & Therapy Recent Anticancer Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.
Current Medicinal Chemistry Future of Spermatogonial Stem Cell Culture: Application of Nanofiber Scaffolds
Current Stem Cell Research & Therapy Cell Death Mechanisms in Stroke and Novel Molecular and Cellular Treatment Options
Current Neuropharmacology Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile
Current Drug Safety Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Current Pharmaceutical Design Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Optimized Radial Basis Neural Network for Classification of Breast Cancer Images
Current Medical Imaging Hck Inhibitors as Potential Therapeutic Agents in Cancer and HIV Infection
Current Medicinal Chemistry Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells
Current Drug Targets Prodrugs of Non-steroidal Anti-inflammatory Drugs (NSAIDs): A Long March Towards Synthesis of Safer NSAIDs
Mini-Reviews in Medicinal Chemistry rDNA Mediated Bioconjugates: Fusion Proteins and their Intended Use in Medicine
Current Topics in Medicinal Chemistry Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry New Treatment Approaches in Acute Myeloid Leukemia: Review of Recent Clinical Studies
Reviews on Recent Clinical Trials Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry